Section Arrow
BBIO.NASDAQ
- BridgeBio Pharma
Quotes are at least 15-min delayed:2026/07/19 08:53 EDT
Regular Hours
Last
 81.38
+1.08 (+1.34%)
Day High 
82.56 
Prev. Close
80.3 
1-M High
93.415 
Volume 
1.44M 
Bid
78.6
Ask
81.38
Day Low
78.98 
Open
79.1 
1-M Low
65.5913 
Market Cap 
15.73B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 81.74 
20-SMA 75.94 
50-SMA 70.69 
52-W High 93.415 
52-W Low 42.0901 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.74/0.60
Enterprise Value
17.58B
Balance Sheet
Book Value Per Share
-11.63
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
77.65M
Operating Revenue Per Share
0.05
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ATAIAtaiBeckley Inc7.22+0.07+0.98%-- 
JSPRJasper Therapeutics0.885+0.111+14.34%-- 
LIMNLiminatus Pharma Inc0.123-0.0247-16.72%-- 
IOVAIovance Biotherapeutics5+0.34+7.30%-- 
RXRXRecursion Pharmaceuticals2.945-0.075-2.48%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.